All In Biotech

Drug Trial Radar · NCT01634061

Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients

Phase Ib Dose Finding Study of Abiraterone Acetate Plus BEZ235 or BKM120 in Patients With Castration-resistant Prostate Cancer.

Last checked: Nov 19, 2026Latest source record: Dec 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

43

Actual

Start

Sep 2012

Primary completion

Jul 2015

Study completion Jul 2015

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 6, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label study of abiraterone acetate in combination with BEZ235 and abiraterone acetate in combination with BKM120 in CRPC patients with abiraterone acetate failure.

Conditions

  • Castration-resistant Prostate Cancer

Interventions

  • BEZ235Drug

    BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.

  • BKM120Drug

    BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.

  • BEZ235Drug

    BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.

  • BKM120Drug

    BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicities (DLTs)Time frame: from days 1-35 in BEZ235/abiraterone acetate arm and from days 1-28 in BKM120/abiraterone acetate arm
  2. Prostate specific antigen (PSA) decline ≥ 30%Time frame: At week 12 or later after treatment discontinuation

Locations

10 sites in 6 countries. Site status is shown where the registry gives one.

  • Cedars Sinai Medical Center SC

    Los Angeles, California

  • Hackensack University Medical Center Hackensack Univ

    Hackensack, New Jersey

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Wilrijk, Belgium

  • Novartis Investigative Site

    Vancouver, British Columbia, Canada

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Villejuif, France

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Sutton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.